September 18, 2018
AngioDynamics to Acquire RadiaDyne
September 13, 2018—AngioDynamics, Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes.
This transaction expands AngioDynamics’ growing oncology business by adding RadiaDyne’s early-stage OarTrac real-time radiation dose monitoring platform and other oncology solutions, including the IsoLoc/ImmobiLoc and Alatus balloon stabilizing technologies.
According to AngioDynamics, RadiaDyne recently launched the OarTrac system, which provides precise, real-time measurement via an intracavitary device. The system delivers critical dose feedback to medical and radiation oncologists, providing customized adaptive radiotherapy, reduced side effects, and improved clinical outcomes across all forms of radiation and photon beam therapy.
Other RadiaDyne products include the IsoLoc/ImmobiLoc endorectal technology, which removes transient rectal gas using a patented gas-release tip and reliably reduces prostate motion and radiation toxicity. RadiaDyne’s Alatus vaginal balloon packing system provides physicians with an improved method for optimal dosimetry protection and decreased complications.